NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials

▴ NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials
Within the scope of this partnership, HALIX will provide manufacturing of clinical supply of NovalGen’s therapies

NovalGen Ltd., a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V., a contract development and manufacturing organisation, today announced a strategic partnership. Within the scope of this partnership, HALIX will provide manufacturing of clinical supply of NovalGen’s therapies.

NovalGen’s innovative platform technology has been successfully deployed at HALIX to manufacture clinical trial material for NovalGen’s first clinical program. The program, NVG-111, is a Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) targeting bispecific antibody T cell engager for the treatment of hematologic malignancies and solid tumours, is expected to enter the clinic in the first half of 2021. HALIX has supported NovalGen with the successful completion of GMP manufacture of NVG-111 from drug substance up to drug product and final release. The strategic partnership and collective expertise of both organisations has ensured an efficient technology transfer and further development of the process leading to a successful GMP manufacturing campaign.

“This collaboration with HALIX will ensure high quality, rapid and secure manufacture of clinical supplies for our current and future products. Using cutting-edge manufacturing technologies at our partner’s state-of-the-art cGMP facility, we are progressing to become a clinical stage company,” said Kieran O’Donovan, SVP Chemistry and Manufacturing Controls at NovalGen.“We developed a manufacturing process around the use of transient transfection to accelerate timelines and reduce costs, whilst delivering product of the highest quality. In HALIX we found the ideal partner; experience in transient transfection, modern facilities, strong leadership and a laser focus on delivery to bring NVG-111 from contract signature to vials of clinical drug in less than seven months.”

“The partnership with NovalGen has been a great success,” said Alex Huybens, Chief Operations Officer at HALIX. “Working closely together and utilizing the collective bispecific antibody expertise of both teams has enabled us to meet the ambitious timelines and efficiently transfer the process and deliver the product to be ready to enter the clinic. We look forward to a long and productive collaboration with NovalGen.”

Tags : #NovalGenLtd #LatestNewsonNovalGenLtd22ndFeb #HALIXBV #LatestNewsonHALIXBV22ndFeb #LatestPharmaNews22ndFeb #LatestPharmaCollaboration22ndFeb #LatestNewsonCancerTherapies

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Are You Struggling with “Maskne”? Find the Top 5 Solutions to deal with it. March 03, 2021
Exercise could well mimic the effects of Polypill , also it's cheaper and without side effectsMarch 03, 2021
Sorrento receives USFDA clearance to start a clinical trial of Anti-CD47 antibodyMarch 03, 2021
Regular breast checks by trained health workers linked to fewer breast cancer deaths in IndiaMarch 03, 2021
Treat Doctors as Friends and Have an Open Chat with Them says Dr. Shailaja Sabnis, Consultant Physician and Rheumatologist March 03, 2021
PM Jan Aushadhi Kendra inaugurated at District Hospital, KargilMarch 02, 2021
Maharashtra records 6,397 new cases of coronavirus todayMarch 02, 2021
One in four people will have hearing problems by 2050: WHOMarch 02, 2021
6 states show surge in Covid-19 cases, India's total active cases reach 1,68,627March 02, 2021
hday for longer life ; American Heart AssociationMarch 02, 2021
Is your baby cranky due to skin complaints? Here are some quick solutions that can help you.March 02, 2021
Women Have the Right to Say “No”, says Dr. Vaishali Joshi, Senior Obstetrician & Gynaecologist, Kokilaben Ambani Hospital, MumbaiMarch 02, 2021
How to Control STDs, explains, Dr. Nikul Patel, Founder and Chief Ayurveda Consultant of Atharva Ayurveda Clinic and Panchakarma Center March 02, 2021
Registration for next phase of COVID19 Vaccination on Co-WIN2.0 portal will open at 9:00 am on 1st MarchMarch 01, 2021
Union Minister Dr. Harsh Vardhan inaugurated major healthcare projects in Imphal yesterdayMarch 01, 2021
AMRI joins network of approved manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 VaccineMarch 01, 2021
Nationwide COVID-19 vaccination drive to cover senior citizens & people with comorbidities begins todayMarch 01, 2021
Johnson & Johnson's Covid-19 vaccine gets emergency use authorization from FDAMarch 01, 2021
“Living with Rheumatoid Arthritis” - Myth Debunked by the Expert Rheumatologist, Dr. Naga PrabhuMarch 01, 2021
Good Sexual Health is Extremely Important for Overall Health of an Individual, says Dr. Vilvapathy Karthikeyan, Consultant AndrologistMarch 01, 2021